Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1803 | Hydroxychloroquine Sulfate 600 mg once a day Wiki | 1.00 |
| drug1804 | Hydroxychloroquine Sulfate 600 mg twice a day Wiki | 1.00 |
| drug2176 | Losartan Wiki | 0.33 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D003141 | Communicable Diseases NIH | 0.07 |
| D007239 | Infection NIH | 0.05 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The PATCH trial (Prevention And Treatment of COVID-19 with Hydroxychloroquine) is funded investigator-initiated trial that includes 3 cohorts. Cohort 1: a double-blind placebo controlled trial of high dose HCQ as a treatment for home bound COVID-19 positive patients; Cohort 2: a randomized study testing different doses of HCQ in hospitalized patients; Cohort 3: a double blind placebo controlled trial of low dose HCQ as a preventative medicine in health care workers.
Description: Cohort 1 (home quarantined COVID-19 patients): Median time to release from quarantine by meeting the following criteria: 1) No fever for 72 hours 2) improvement in other symptoms and 3) 7 days have elapsed since the beginning of symptom onset.
Measure: Median release from quarantine time Time: 14 days or lessDescription: Cohort 2 (hospitalized COVID-19 patients): Rate of participants discharged at or before 14 days
Measure: Rate of hospital discharge Time: 14 daysDescription: Cohort 3 Physicians and nurse prophylaxis: Rate of COVID-19 infection at 2 months
Measure: Rate of infection Time: 2 monthsDescription: Cohort 1 rate of participant-reported secondary infection of housemates
Measure: Rate of housemate infection Time: 14 daysDescription: Cohort 1 rate of hospitalization
Measure: Rate of hospitalization Time: 14 daysDescription: Cohort 1 rate of treatment related adverse events
Measure: Cohort 1 adverse event rate Time: 14 daysDescription: Cohort 2 Time to condition appropriate for discharge. The primary care team indicates the patients has improved to the point of being discharged.
Measure: Time to condition appropriate for discharge Time: 14 daysDescription: Cohort 2 rate of ICU admission from a floor bed in the hospital
Measure: Rate of ICU admission Time: 14 daysDescription: Cohort 2 the number of days between hospital admission and a negative PCR test for SARS-CoV-2.
Measure: Time to PCR negativity Time: 14 daysDescription: Cohort 2 rate of treatment related adverse events
Measure: Cohort 2 adverse events Time: 14 daysDescription: Cohort 3 number of scheduled shifts at the hospital that are missed.
Measure: Scheduled shifts missed Time: 2 monthsDescription: Cohort 3 rate of treatment related adverse events
Measure: Cohort 3 adverse events Time: 2 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports